Amitiza end-payors, direct purchasers get class certification in US antitrust case
MLex Summary: End-payor and direct purchaser plaintiffs accusing Takeda Pharmaceuticals of delaying a generic version of the drug Amitiza won class certification in their US antitrust case. However, US District Judge...To view the full article, register now.
Already a subscriber? Click here to view full article